Literature DB >> 19553571

Proteomic identification of OprL as a seromarker for initial diagnosis of Pseudomonas aeruginosa infection of patients with cystic fibrosis.

Aparna R Rao1, Anita Laxova, Philip M Farrell, Joseph T Barbieri.   

Abstract

Identification of new immunogenic antigens that diagnose initial Pseudomonas aeruginosa infections in patients with cystic fibrosis (CF) alone or as an adjunct to microbiology is needed. In the present study, a proteomic analysis was performed to obtain a global assessment of the host immune response during the initial P. aeruginosa infection of patients with CF. Matrix-assisted laser desorption ionization-time of flight mass spectrometry was used to identify outer membrane protein L (OprL), a non-type III secretion system (TTSS) protein, as an early immunogenic protein during the initial P. aeruginosa infection of patients with CF. Longitudinal Western blot analysis of sera from 12 of 14 patients with CF detected antibodies to OprL during the initial P. aeruginosa infection. In addition, also detected were antibodies to ExoS, ExoU, or ExoS and ExoU, the latter indicating sequential P. aeruginosa infections during initial infections. Detection of serum reactivity to OprL, along with proteins of the TTSS, and in conjunction with microbiology may diagnose initial P. aeruginosa infections in patients with CF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19553571      PMCID: PMC2725635          DOI: 10.1128/JCM.02182-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  45 in total

1.  Recognition of host immune activation by Pseudomonas aeruginosa.

Authors:  Licheng Wu; Oscar Estrada; Olga Zaborina; Manjeet Bains; Le Shen; Jonathan E Kohler; Nachiket Patel; Mark W Musch; Eugene B Chang; Yang-Xin Fu; Michael A Jacobs; Michael I Nishimura; Robert E W Hancock; Jerrold R Turner; John C Alverdy
Journal:  Science       Date:  2005-07-29       Impact factor: 47.728

Review 2.  Detection of Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  G A Tramper-Stranders; C K van der Ent; T F W Wolfs
Journal:  J Cyst Fibros       Date:  2005-08       Impact factor: 5.482

3.  ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury.

Authors:  V Finck-Barbançon; J Goranson; L Zhu; T Sawa; J P Wiener-Kronish; S M Fleiszig; C Wu; L Mende-Mueller; D W Frank
Journal:  Mol Microbiol       Date:  1997-08       Impact factor: 3.501

4.  An outer membrane protein characteristic of mucoid strains of Pseudomonas aeruginosa.

Authors:  E Grabert; J Wingender; U K Winkler
Journal:  FEMS Microbiol Lett       Date:  1990-03-01       Impact factor: 2.742

5.  Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.

Authors:  Zhanhai Li; Michael R Kosorok; Philip M Farrell; Anita Laxova; Susan E H West; Christopher G Green; Jannette Collins; Michael J Rock; Mark L Splaingard
Journal:  JAMA       Date:  2005-02-02       Impact factor: 56.272

6.  Antilipopolysaccharide antibodies and differential diagnosis of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.

Authors:  A Fomsgaard; B Dinesen; G H Shand; T Pressler; N Høiby
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

7.  Pseudomonas aeruginosa-mediated cytotoxicity and invasion correlate with distinct genotypes at the loci encoding exoenzyme S.

Authors:  S M Fleiszig; J P Wiener-Kronish; H Miyazaki; V Vallas; K E Mostov; D Kanada; T Sawa; T S Yen; D W Frank
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

Review 8.  The exoenzyme S regulon of Pseudomonas aeruginosa.

Authors:  D W Frank
Journal:  Mol Microbiol       Date:  1997-11       Impact factor: 3.501

9.  Early infection and progression of cystic fibrosis lung disease.

Authors:  Christian Koch
Journal:  Pediatr Pulmonol       Date:  2002-09

10.  Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis.

Authors:  G Döring; N Høiby
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

View more
  5 in total

1.  Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia.

Authors:  Weihui Wu; Jin Huang; Biyan Duan; David C Traficante; Haeyeon Hong; Martina Risech; Stephen Lory; Gregory P Priebe
Journal:  Am J Respir Crit Care Med       Date:  2012-06-21       Impact factor: 21.405

2.  Protein biomarkers in cystic fibrosis research: where next?

Authors:  Sally H Pattison; J Stuart Elborn
Journal:  Genome Med       Date:  2010-12-16       Impact factor: 11.117

3.  Detection of Cystic Fibrosis Serological Biomarkers Using a T7 Phage Display Library.

Authors:  Harvinder Talwar; Samer Najeeb Hanoudi; Andreea Geamanu; Dana Kissner; Sorin Draghici; Lobelia Samavati
Journal:  Sci Rep       Date:  2017-12-18       Impact factor: 4.379

Review 4.  Understanding Pseudomonas aeruginosa-Host Interactions: The Ongoing Quest for an Efficacious Vaccine.

Authors:  Maite Sainz-Mejías; Irene Jurado-Martín; Siobhán McClean
Journal:  Cells       Date:  2020-12-05       Impact factor: 6.600

5.  Highly sensitive and rapid detection of Pseudomonas aeruginosa based on magnetic enrichment and magnetic separation.

Authors:  Yongjun Tang; Jun Zou; Chao Ma; Zeeshan Ali; Zhiyang Li; Xiaolong Li; Ninging Ma; Xianbo Mou; Yan Deng; Liming Zhang; Kai Li; Guangming Lu; Haowen Yang; Nongyue He
Journal:  Theranostics       Date:  2013-01-16       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.